Applicability of a structure-based modelling approach as a tool for in silico screening of oligonucleotides for targeted RNA editing presented at Oligonucleotide Therapeutics Society (OTS) 2018 by Julien Boudet
… vivo proof of concept data will be presented at upcoming Oligonucleotide Therapeutics Society (OTS) Meeting on … by Endogenous ADAR Enzymes” will be presented during the Oligonucleotide Therapeutics Society (OTS) Meeting to be held …
… stable in CF mucus: During the 12th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) September 25 – 28, … p.Cys998X mutation. During the 12th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS), the company also …
Received CTA authorization for Phase 1 trial of lead program AX-0810, targeting NTCP for cholestatic diseasesInitiating Phase 1 study of AX-0810 in healthy volunteers, with initial safety, tolerability, and PK data from Cohort 1 expected by year-end, and target engagemen
… interim data also expected in 2018. Spin-out of Amylon Therapeutics as a privately-held company focused on central … Axiomer ® RNA editing technology platform at the OligonucleotideTherapeuticsSociety (OTS) meeting in Bordeaux, France and at the Drug …
